← ACADIA Pharmaceuticals Inc. (ACAD) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
ACADIA Pharmaceuticals Inc. (ACAD)
Pharmaceutical Preparations · market cap $4.4B · as of 2026-07-14
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-04 (est.)
Earnings
Pipeline
13
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
ACADIA Pharmaceuticals (ACAD) is a ~$4.5B market cap specialty biopharmaceutical company with an approved franchise in Parkinson's Disease Psychosis (pimavanserin tartrate) generating $1.07B in 2025 revenue and $391M net income. The company is pursuing label expansions and new indications across dementia-related psychosis, Alzheimer's agitation, Rett syndrome, Lewy Body Dementia, and several earlier-stage CNS assets, with the next public event being an August 2026 earnings release.
The catalyst path
- 2026-11-04 (est.)Earningsimp 5/10
- 2027-01-15 (est.)Phase 2 · Pimavanserin 34 mgimp 7/10
- 2027-08-15 (est.)Phase 2 · ACP-211imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| ACP-044 Dose A | Phase 2 | Acute Postoperative Pain |
| Pimavanserin 34 mg | Phase 3 | Dementia-related Psychosis |
| ACP-103 | Phase 2 | Hallucinations |
| pimavanserin tartrate | Phase 3 | Parkinson's Disease Psychosis |
| Trofinetide | Phase 3 | Rett Syndrome |
| Pimavanserin tartrate (ACP-103) | Phase 3 | Parkinson's Disease Psychosis |
| ACP-104 | Phase 2 | Schizophrenia |
| Carbetocin | Phase 3 | Hyperphagia in Prader-Willi Syndrome |
| ACP-211 | Phase 2 | Major Depressive Disorder (MDD) |
| Pimavanserin | Phase 3 | Agitation and Aggression in Alzheimer's Disease |
| ACP-204 | Phase 3 | Lewy Body Dementia Psychosis |
| Active drug: pimavanserin 17mg (2 strength tablets) | Phase 2 | Parkinson Disease |
| Pimavanserin Tartrate 34 Mg ORAL CAPSULE [NUPLAZID] | Phase 2 | Autism Spectrum Disorder |
Price & technical context
3-month
-22.4%
6-month
-9.9%
12-month
-6.5%
52-wk range
$19.89–$30.57
vs 50-day MA
-25.8%
vs 200-day MA
-18.0%
Realized vol
42.0%
Max drawdown
-34.9%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ACAD (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 13 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.